

Therapeutic Area	Phase1	Phase2	Phase3	Application
Cardiovascular-Metabolics	<p>CS-3150 (Antihypertensive)</p> <p>DS-7309 (Anti-diabetes)</p> <p>DS-7250 (Anti-diabetes)</p>		<p>DU-176b (US/EU/JP/Asia) (Edoxaban / AF / oral factor Xa inhibitor)</p> <p>DU-176b (US/EU/JP/Asia) (Edoxaban / VTE / oral factor Xa inhibitor)</p> <p>CS-747 (US/EU/Asia) (Prasugrel / ACS-MM / anti-platelet agent)</p> <p>CS-747 (JP) (Prasugrel / PCI / anti-platelet agent)</p> <p>CS-747 (JP) (Prasugrel / ischemic stroke / anti-platelet agent)</p>	
Oncology	<p>CS-7017 (JP/Asia) (Efatutazone / PPARγ agonist)</p> <p>U3-1565 (US/JP) (Anti-HB-EGF antibody)</p> <p>U3-1287 (JP) (Anti-HER3 antibody)</p> <p>DS-2248 (US) (Hsp90 inhibitor)</p> <p>DS-7423 (US) (PI3K/mTOR inhibitor)</p> <p>ARQ 092 (US) (AKT inhibitor)</p>	<p>U3-1287 (US/EU) (Anti-HER3 antibody)</p> <p>CS-1008 (US/EU/JP/Asia) (Tigatuzumab / anti-DR5 antibody)</p> <p>CS-7017 (US/EU) (Efatutazone / PPARγ agonist)</p> <p>DE-766 (JP) (Nimotuzumab / anti-EGFR antibody)</p> <p>PLX3397 (US) (Fms/Kit/Flt3-ITD inhibitor)</p>	<p>ARQ 197 (US/EU) (Tivantinib / NSCLC / c-Met inhibitor)</p> <p>AMG 162 (JP) (Denosumab / breast cancer adjuvant / anti-RANKL antibody)</p>	<p>PLX4032 (EU) (Vemurafenib / Melanoma / BRAF inhibitor)</p> <p>AMG 162 (JP) (Denosumab / bone metastases of cancer / anti-RANKL antibody)</p>
Infectious diseases	<p>CS-8958 (US/EU) (Laninamivir / anti-influenza / Outlicensing with Biota)</p> <p>CS-4771 (Anti-Sepsis)</p> <p>DS-8587 (Broad spectrum antibacterial agent)</p>		<p>CS-8958 (JP) (Laninamivir / anti-influenza, prophylactic / Neuraminidase inhibitor)</p>	
Bone/Joint diseases	<p>PLX5622 (Rheumatoid arthritis)</p>	<p>AMG 162 (JP) (Denosumab / rheumatoid arthritis / anti-RANKL antibody)</p>	<p>AMG 162 (JP) (Denosumab / osteoporosis / anti-RANKL antibody)</p>	
Immunological allergic diseases	<p>CS-0777 (Immunomodulator)</p>	<p>SUN13834 (US) (Atopic Dermatitis / Chymase inhibitor)</p>		
Others	<p>SUN13837 (Spinal cord injury)</p>	<p>DS-5565(US/JP) (Chronic pain / $\alpha 2 \delta$ ligand)</p>	<p>SUN11031 (JP) (Human ghrelin / anorexia nervosa)</p> <p>DD-723-B (JP) (Perflubutane / Contrast enhanced ultrasonography for prostate cancer / ultrasound contrast agent)</p>	<p>DD-723-B (JP) (Perflubutane / Contrast enhanced ultrasonography for breast tumor/ ultrasound contrast agent)</p>

Change from the announcement in October 2011

New DS-7250(Anti-diabetes), ARQ 092(AKT inhibitor/US)

Change of Stage AMG 162(Denosumab / bone metastases of cancer / anti-RANKL antibody / JP / Approved), DD-723-B(Perflubutane / Contrast ultrasonography for breast tumor/ ultrasound contrast agent / JP/ Application)
DS-5565(Chronic pain / $\alpha 2 \delta$ ligand / US/JP / P2)